Gawryl M S, Chudwin D S, Langlois P F, Lint T F
Department of Immunology/Microbiology, Rush-Presbyterian-St. Luke's Chicago 60612.
Arthritis Rheum. 1988 Feb;31(2):188-95. doi: 10.1002/art.1780310206.
Concentrations of the terminal complement complex (TCC), C5b-9, were examined in 120 serum samples from 28 patients with systemic lupus erythematosus. Eleven patients with various manifestations of the disease were followed longitudinally for a 2-year period during active and inactive phases of the disease. In 9 of the 11 patients, elevations in TCC concentrations correlated with disease exacerbations. In many of these patients, C3 and C4 levels remained normal during the study and were less sensitive indicators of disease activity than were TCC concentrations. We believe that measurements of TCC are useful in monitoring patients with rheumatic diseases in which complement activation is a component.
检测了28例系统性红斑狼疮患者120份血清样本中终末补体复合物（TCC，即C5b - 9）的浓度。对11例有该疾病各种表现的患者在疾病的活动期和非活动期进行了为期2年的纵向随访。在这11例患者中的9例中，TCC浓度升高与疾病加重相关。在这些患者中的许多人，C3和C4水平在研究期间保持正常，并且与TCC浓度相比，它们作为疾病活动指标的敏感性较低。我们认为，TCC的检测对于监测补体激活是其中一个组成部分的风湿性疾病患者是有用的。
